$2.5M seed financing round closed by Cleara Biotech-targets cellular senescence
Longevity Technology - 03-Oct-2022Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells
Join the club for FREE to access the whole archive and other member benefits.
Associate Professor at UMC Utrecht, Founder and Managing Director at Cleara Biotech
Peter de Keizer is the founder and managing director of Cleara Biotech B.V. He has 10+ years experience in valorization, intellectual property and preclinical research and development. He is and associate professor “Senescence in Cancer and Aging” at the University Medical Center Utrecht, the Netherlands. Peter was trained as a molecular biologist at Utrecht University and Harvard Medical School / Mass General Hospital, Boston, MA, USA (2004). He performed is PhD in 2009 in the field of FOXO signaling, knowledge he employed during his postdoctoral work at the Buck Institute for Research on Aging in Novato, CA, USA (2012) to develop the first compounds to eliminate senescent cells: FOXO4-based peptides. In 2017, he showed the translational power eliminating at least some types of senescent cells in mice, which resulted in a restoration of tissue homeostasis in models for aging and chemotoxicity (Cell, 2017; cited >700 times). In 2018, he joined the UMC Utrecht, the Netherlands, to investigate subtypes of senescence, where he became associate professor in 2020.
Visit website: https://www.clearabiotech.com/team/
See also: Cleara Biotech - Cleara is developing therapeutics to eliminate senescent cells.
Details last updated 03-Jun-2019
31-Aug-2021 to 03-Sep-2021
Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.
25-May-2022 to 27-May-2022
Virtual conference by Wellcome Connecting Science with Judith Campisi as a keynote speaker
Cleara’s novel FOXO4-based treatment approach-ability to eliminate biomarker-positive scarred cells
In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
General feeling that failures are bound to happen - but that their approaches can succeed
Encouraging signs from big companies - more interviews to follow
This therapy uses a modified FOXO4 to promote apoptosis in senescent cells
Study directly targets one of the mechanisms that senescent cells use to avoid apoptosis, Focuse...
Growing older results in a build-up of the body’s senescent cells and naturally accumulate with a...
Peter de Keizer of the Erasmus University Medical Center discusses strategy of removing senescent...
Peter de Keizer of the Erasmus University Medical Center discusses strategy of removing senescent...